Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2005
11/10/2005WO2004082640A8 Human serum albumin conjugates with therapeutic compounds
11/10/2005US20050250939 Process for the production of multiple cross-linked hyaluronic acid derivatives
11/10/2005US20050250933 Vaccines
11/10/2005US20050250881 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds
11/10/2005US20050250852 For facilitating the delivery of active agents, such as insulin, to a target
11/10/2005US20050250848 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
11/10/2005US20050250813 Injectable depot formulation comprising crystals of iloperidone
11/10/2005US20050250778 Topical brimonidine tartrate formulations that lack chlorine dioxide
11/10/2005US20050250764 Solution of an HIV protease inhibitor in a combination of suitable pharmaceutical organic solvents, a surfactant and a bioavailability enhancer; suitable for the preparation of oral solutions for the administration of active drugs and for encapsulation in hard gelatin capsules or soft gelatin capsules
11/10/2005US20050250756 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
11/10/2005US20050250755 administering to the patient an effective amount of a pharmaceutical formulation comprising:reaction products resulting from oxidation of menthol or an alkene such as geraniol by an oxygen-containing oxidizing agent; a penetrating solvent dimethylsulfoxide; a chelated dye; and an aromatic redox compound
11/10/2005US20050250737 Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
11/10/2005US20050250736 Composition and method for treatment of obesity and smoking cessation
11/10/2005US20050250718 Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity
11/10/2005US20050250696 Truncated soluble tumor necrosis factor type-I and type-II receptors
11/10/2005US20050250683 Delivering molecules to cells; crosslinking; reverse charging; complex of lipid with maleic anhydride containing compound
11/10/2005US20050250679 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
11/10/2005US20050250175 Bacterial cell wall skeleton component preparaion
11/10/2005US20050249857 Lignan complexes
11/10/2005US20050249839 Enzyme preparation and process for producing food using the same
11/10/2005US20050249818 Polycationic antimicrobial therapeutic
11/10/2005US20050249814 Solubility of hydrophobic drugs with a compound having a carboxylic acid moiety
11/10/2005US20050249810 Film coating for tablets and caplets
11/10/2005US20050249797 Self forming, thermodynamically stable liposomes and their applications
11/10/2005US20050249786 Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
11/10/2005US20050249782 Drug delivery device
11/10/2005US20050249778 Carboxylated polysaccharides and method of preparation and use
11/10/2005US20050249770 Compositions and methods for treating or preventing inflammatory diseases
11/10/2005US20050249757 Pharmaceutical cream formulations
11/10/2005US20050249756 Use of human prostate cell lines in cancer treatment
11/10/2005US20050249740 with cyclodextrins, polyoxyethylene glycol; anticancer agents
11/10/2005US20050249738 Immunotoxins directed against malignant cells
11/10/2005US20050249730 Novel anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
11/10/2005US20050249727 Prevention and treatment of amyloidogenic disease
11/10/2005US20050249725 Improving cognitive function of individuals with beta amyloid disfunction utilizing beta amyloid specific immunoglobulin; immunotherapeutics
11/10/2005US20050249721 Compositions and methods for targeted biological delivery of molecular carriers
11/10/2005US20050249714 Method of using secretin and compositions made therefrom for the treatment of autism and other neurological, behavioral and immunological disorders
11/10/2005US20050249710 biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
11/10/2005US20050249701 Il-7 Drug substance, composition, preparation and uses
11/10/2005US20050249681 Use of diketopiperazine derivatives as photostable uv-filters in cosmetic and pharmaceutical preparations
11/10/2005US20050249671 Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
11/10/2005US20050249663 Coadministration of transport protein with conjugated cobalamin to deliver agents
11/10/2005DE202004020676U1 Storage-stable liquid erythropoietin formulation, for treatment of renal insufficiency, comprises specified amino acids but no preservatives, urea or albumen and is not a reconstituted lyophilizate
11/10/2005DE102004019323A1 Mit toxischen Substanzen beladene dendritische Zellen zur Behandlung von Nierenzellkarzinomen With toxic substances loaded dendritic cells for the treatment of renal cell carcinoma
11/10/2005CA2686815A1 Therapeutic antimicrobial compositions and methods
11/10/2005CA2595116A1 Oral formulation for delivery of poorly absorbed drugs
11/10/2005CA2579767A1 Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
11/10/2005CA2565941A1 Improved nsaid composition
11/10/2005CA2565633A1 Lipids, lipid complexes and use thereof
11/10/2005CA2565382A1 Use of a viscoelastic composition for treating increased intraocular pressure
11/10/2005CA2564982A1 Pegylated nanoparticles
11/10/2005CA2564674A1 Drying process for preserving an active agent as a highly viscous liquid
11/10/2005CA2564366A1 Combined meningococcal conjugates with common carrier protein
11/10/2005CA2564234A1 Dermally applicable liquid formulations for controlling parasitic arthropods on animals
11/10/2005CA2563957A1 Low molecular weight polylactic acid polymers
11/10/2005CA2563829A1 Process for the selective increase of a release rate of an active material from a pharmaceutical composition
11/10/2005CA2563263A1 Embolization
11/10/2005CA2562962A1 Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
11/10/2005CA2562952A1 Regiospecific synthesis of rapamycin 42-ester derivatives
11/10/2005CA2562919A1 Aqueous solutions comprising prednisolone and a cyclodextrin derivative
11/10/2005CA2562585A1 Dpi formulation containing sulfoalkyl ether cyclodextrin
11/10/2005CA2562527A1 Polymer conjugate releasable under mild thiolytic conditions
11/10/2005CA2559918A1 Liquid growth hormone formulation
11/09/2005EP1593406A1 Device for electrochemotherapy and pharmaceutical preparation comprising the same
11/09/2005EP1593395A2 Gas filled microspheres as magnetic resonance imaging contrast agents
11/09/2005EP1593382A1 Use of probiotic lactic bacteria for balancing the skin's immune system
11/09/2005EP1593377A1 Crosslinkable macromers bearing initiator groups
11/09/2005EP1593127A2 Radiation protection by gamma-tocotrienol
11/09/2005EP1592457A2 Vitamin receptor binding drug delivery conjugates
11/09/2005EP1592453A1 Multiparticulate compositions of milnacipran for oral administration
11/09/2005EP1592452A2 Invert emulsion type composition containing at least one active agent sensitive to the presence of water, and its uses in cosmetics and in dermatology
11/09/2005EP1592451A1 Stable dispersion of solid particles comprising a water-insoluble pyrazine compound
11/09/2005EP1592450A2 Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions
11/09/2005EP1592447A1 Devices and compositions containing boron and silicon for use in neutron capture therapy
11/09/2005EP1592435A1 Ophthalmic formulation for the prevention and treatment of ocular conditions
11/09/2005EP1592432A2 Modified polysaccharides combination with anti-cancer drugs for enhanced treatment of cancer
11/09/2005EP1592415A2 Therapeutically active compounds
11/09/2005EP1592412A1 Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
11/09/2005EP1592402A2 Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
11/09/2005EP1480990B1 Compounds for use as surfactants
11/09/2005EP1463732A4 Hydroxycucurbituril derivatives, their preparation methods and uses
11/09/2005EP1418891B1 Anaesthetic formulations of propofol
11/09/2005EP1365748B1 Particulate composition of eletriptan hydrobromide showing a sigmoidal pattern of controlled release
11/09/2005EP1282393B1 External application for enhancing the skin permeability of the active components therein
11/09/2005EP1212069B1 Improved topical compositions containing extracellular products of probiotic bacteria and uses thereof
11/09/2005EP1173218B1 Mucosally adhesive compositions for the treatment of disorders of the oesophagus and their use.
11/09/2005EP1149066B1 Method of preparing alkylated salicylamides
11/09/2005EP1131055B1 Treatment set containing lungsurfactant compositions
11/09/2005EP1130964B1 Therapeutic anti-fungal nail preparation
11/09/2005EP1113023B1 Method of forming agglomerates of polysaccharide with hydrophobic groups
11/09/2005EP1019365B1 Novel compositions for the delivery of negatively charged molecules
11/09/2005EP1019089B1 Long-acting drugs and pharmaceutical compositions comprising them
11/09/2005EP1011722B1 Substrates materials with bound cytokine-stimulating polysaccharides or bacterial nucleic acids
11/09/2005EP0975227B1 Topical use of probiotic bacillus spores to prevent or control microbial infections
11/09/2005EP0971745B1 Gel delivery vehicles for anticellular proliferative agents
11/09/2005EP0772455B1 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
11/09/2005CN1694938A Spraying composition
11/09/2005CN1694895A Modified transferrin-antibody fusion proteins
11/09/2005CN1694867A Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same
11/09/2005CN1694736A Medical devices containing rapamycin analogs
1 ... 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 ... 1712